Pacira BioSciences, Inc. is a pharmaceutical company headquartered in Brisbane, California, focused on transforming how the world treats pain.
Subscribe to see Pacira BioSciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Pacira BioSciences, Inc. is a pharmaceuticals company headquartered in Brisbane, United States. It is publicly listed (PCRX) with a market capitalisation of $1.4B. Xcout tracks 27 named people at Pacira BioSciences, Inc., including Frank D. Lee (Chief Executive Officer & Director).
21 more named people on record for Pacira BioSciences, Inc., with roles, board committees and tenure — see the full roster →
A few of Pacira BioSciences, Inc.'s closest competitors — see the full list of competitors and alternatives →
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
Santen Pharmaceutical Co., Ltd. is headquartered in Osaka, Japan, and is a global leader in ophthalmological research, development, production, and marketing of related pharmaceuticals and medical devices.
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative implantable medical devices. The firm aims to address chronic diseases for which current treatments are insufficient or lacking. Its key initiatives include a portfolio of miniature drug implants, designed to ensure consistent and stable therapeutic drug delivery, as well as advanced implantable visual prostheses intended to provide meaningful artificial vision to blind individuals. Vivani Medical is headquartered in Emeryville, California.
Bexson Biomedical is a US-based biopharmaceutical company situated in Santa Barbara, California, focused on the research and development of non-opioid therapeutics and drug delivery systems.
Vector Science and Therapeutics Corp. is a medical technology and therapeutic delivery company that develops and sells biomechanical devices and active localized drug delivery platforms. Headquartered in Mequon, Wisconsin, the company focuses on providing clinicians with non-systemic, site-directed technologies. It is publicly listed on the TSXV under the ticker PAIN.V.
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.